AbbVie Needed To Study Heart Impact Of AndroGel, Jury Told
An expert on pharmaceutical regulation testifying in a trial against AbbVie Inc. over testosterone therapy drug AndroGel told an Illinois federal jury Friday that there was enough evidence of a connection...To view the full article, register now.
Already a subscriber? Click here to view full article